Our Approach

Intellectual Property

Sagene has discovered and patented novel actions of selegiline, a selective MAO-B inhibitor and FDA-approved neuroprotective drug for the treatment of Parkinson’s disease as adjunctive therapy and as monotherapy for Major Depressive Disorder.

Sagene‚Äôs patent portfolio includes two issued patents covering vascular actions of MAO-A and MAO-B inhibitors and several awarded and/or pending patents for its proprietary combinations to treat erectile dysfunction (ED), pulmonary arterial hypertension (PAH), pain/inflammation and cardiovascular diseases. Sagene’s patents cover a wide landscape of beneficial agents which could be used to develop drugs in combination with MAO-A and MAO-B inhibitors. Sagene was recentlyissued a US Patent for the treatment of ED.